What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Gene
The scientist’s investigation covers issues in Ankylosing spondylitis, Internal medicine, Spondylitis, Immunology and Surgery.
His Ankylosing spondylitis study incorporates themes from Psoriatic arthritis, Infliximab, Physical therapy, Severity of illness and Etanercept.
Internal medicine is closely attributed to Gastroenterology in his work.
His research on Spondylitis also deals with topics like
- Genome-wide association study that connect with fields like Human leukocyte antigen, Bioinformatics and Genetic predisposition,
- Sacroiliac joint and related Nuclear medicine.
The Immunology study which covers Single-nucleotide polymorphism that intersects with Haplotype, Allele and Attributable risk.
His Surgery research is multidisciplinary, incorporating elements of Placebo, Placebo-controlled study and Syndesmophyte.
His most cited work include:
- Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. (627 citations)
- Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility (608 citations)
- 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis (605 citations)
What are the main themes of his work throughout his whole career to date?
Robert D. Inman mainly focuses on Ankylosing spondylitis, Immunology, Internal medicine, Arthritis and Physical therapy.
His specific area of interest is Ankylosing spondylitis, where he studies Spondylitis.
His studies in Immune system, Reactive arthritis, Antigen, Pathogenesis and Human leukocyte antigen are all subfields of Immunology research.
His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Surgery.
His research integrates issues of Back pain and Axial spondyloarthritis in his study of Physical therapy.
His work carried out in the field of Placebo brings together such families of science as Golimumab and Randomized controlled trial.
He most often published in these fields:
- Ankylosing spondylitis (49.09%)
- Immunology (44.47%)
- Internal medicine (32.19%)
What were the highlights of his more recent work (between 2015-2021)?
- Ankylosing spondylitis (49.09%)
- Immunology (44.47%)
- Internal medicine (32.19%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Ankylosing spondylitis, Immunology, Internal medicine, Axial spondyloarthritis and Spondylitis.
Robert D. Inman interconnects Physical therapy, BASDAI and Disease, Inflammatory bowel disease in the investigation of issues within Ankylosing spondylitis.
Monocyte, Signal transduction and Chlamydia muridarum is closely connected to Receptor in his research, which is encompassed under the umbrella topic of Immunology.
His Internal medicine research includes elements of Gastroenterology, Placebo, Surgery and Default mode network.
His Axial spondyloarthritis course of study focuses on Quality of life and Somewhat Worse, Ankylosing Spondylitis Quality of Life and Receiver operating characteristic.
As a part of the same scientific family, Robert D. Inman mostly works in the field of Spondylitis, focusing on Back pain and, on occasion, Biomarker and Patient advocacy.
Between 2015 and 2021, his most popular works were:
- 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis (605 citations)
- American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. (299 citations)
- Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force (260 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Gene
Ankylosing spondylitis, Immunology, Spondylitis, Physical therapy and Chronic pain are his primary areas of study.
Ankylosing spondylitis is a primary field of his research addressed under Internal medicine.
His Immunology research is multidisciplinary, relying on both Receptor and Cell migration.
The various areas that Robert D. Inman examines in his Spondylitis study include Transcription factor, HLA-B27, Immune system and Medical genetics.
His Physical therapy research is multidisciplinary, incorporating elements of Adalimumab, Psoriatic arthritis, Infliximab, Axial spondyloarthritis and Evidence-based medicine.
His studies deal with areas such as Resting state fMRI, Default mode network and Brain mapping as well as Chronic pain.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
